Literature DB >> 3353206

Comparison of the in vitro dissolution properties and in vivo steady-state pharmacokinetics of two sustained-release theophylline preparations.

J H Jonkman1, W J Van der Boon, G Grasmeijer.   

Abstract

The sustained-release properties and relative bioavailability of Theolin Retard and Pharphylline Retard were studied in eight healthy adults after treatment for five days with twice daily 450 mg, respectively 425 mg. During the day-time dosing interval on the fourth and fifth day theophylline plasma concentrations were assayed by HPLC. After intake of Theolin Retard, minimum theophylline plasma concentrations were significantly higher, fluctuations in theophylline plasma concentrations were significantly smaller and t75 (the period within a dosing interval during which the plasma concentration exceeds 75% of the maximal concentration) was significantly longer than after Pharphylline Retard. Maximal concentrations and AUC values were not significantly different. For both products the plasma concentration time-curves on day 5 were significantly lower than on day 4. In vitro dissolution tests confirmed the more sustained release of theophylline from Theolin Retard. These results indicate an equal extent of absorption from the two products but better sustained-release properties for Theolin Retard.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3353206     DOI: 10.1007/bf01966430

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  15 in total

1.  Sustained-release theophylline for childhood asthma: evidence for circadian variation of theophylline pharmacokinetics.

Authors:  P H Scott; E Tabachnik; S MacLeod; J Correia; C Newth; H Levison
Journal:  J Pediatr       Date:  1981-09       Impact factor: 4.406

2.  Relationship of formulation and dosing interval to fluctuation of serum theophylline concentration in children with chronic asthma.

Authors:  M Weinberger; L Hendeles; L Wong
Journal:  J Pediatr       Date:  1981-07       Impact factor: 4.406

3.  The effectiveness of the short- and long-term use of crystallized theophylline in asthmatic children.

Authors:  R M Katz; G S Rachelefsky; S Siegel
Journal:  J Pediatr       Date:  1978-04       Impact factor: 4.406

4.  Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults.

Authors:  J H Jonkman; W J van der Boon; L P Balant; R Schoenmaker; A Holtkamp
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Studies on theophylline metabolism: autoinduction and inhibition by antipyrine.

Authors:  C L Denlinger; K K Stryker; L B Slusher; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1987-05       Impact factor: 6.875

6.  Separate and combined use of terbutaline and theophylline in asthmatics. Effects related to plasma levels.

Authors:  B Billing; R Dahlqvist; M Garle; Y Hörnblad; E Ripe
Journal:  Eur J Respir Dis       Date:  1982-09

7.  Pharmacokinetic analysis of the disposition of intravenous theophylline in young children.

Authors:  P M Loughnan; D S Sitar; R I Ogilvie; A Eisen; Z Fox; A H Neims
Journal:  J Pediatr       Date:  1976-05       Impact factor: 4.406

8.  Theophylline pharmacokinetics in the young infant.

Authors:  J P Rosen; M Danish; M C Ragni; C L Saccar; S J Yaffe; H I Lecks
Journal:  Pediatrics       Date:  1979-08       Impact factor: 7.124

9.  Pharmacokinetics of theophylline in infancy.

Authors:  F E Simons; K J Simons
Journal:  J Clin Pharmacol       Date:  1978-10       Impact factor: 3.126

Review 10.  Theophylline. A "state of the art" review.

Authors:  L Hendeles; M Weinberger
Journal:  Pharmacotherapy       Date:  1983 Jan-Feb       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.